Paritaprevir, ritonavir, ombitasvir, and dasabuvir treatment in renal transplant patients with hepatitis C virus infection


Creative Commons License

DANIŞ N., TÖZ H. , ÜNAL N. G. , YILMAZ M. , TURAN İ. , GÜNŞAR F. , ...Daha Fazla

TURKISH JOURNAL OF GASTROENTEROLOGY, cilt.30, ss.695-701, 2019 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 30 Konu: 8
  • Basım Tarihi: 2019
  • Doi Numarası: 10.5152/tjg.2019.18833
  • Dergi Adı: TURKISH JOURNAL OF GASTROENTEROLOGY
  • Sayfa Sayıları: ss.695-701

Özet

Background/Aims: The Social Security System of our country reimburses only paritaprevir, ritonavir, ombitasvir, and dasabuvir (PrOD) regime in treatment-naive patients with hepatitis C regardless of kidney disease. Most of our renal transplant (RT) recipients were treated with PrOD. The aim of the present study was to investigate the efficacy and safety of PrOD in RT patients with hepatitis C virus (HCV) infection in a single center real-life experience.